Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound-Enhanced Uptake of Chemotherapy in Inoperable Pancreatic Ductal Adenocarcinoma
2019-001736-57Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulfur hexafluoride in pancreatic adenocarcinoma (PDAC), sponsored by St. Olavs University Hospital. Primary endpoint: Primary: Change in PDAC tumor volume after 1 treatment cycle. Started May 2019; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2019-001736-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001736-57.